IRIS
PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.202
EU - Europa 4.149
AS - Asia 3.755
AF - Africa 601
SA - Sud America 581
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.302
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.934
SG - Singapore 1.782
IT - Italia 1.376
RU - Federazione Russa 1.226
CN - Cina 1.025
BR - Brasile 468
IE - Irlanda 413
CI - Costa d'Avorio 307
UA - Ucraina 282
VN - Vietnam 269
FR - Francia 199
CA - Canada 189
KR - Corea 188
DE - Germania 187
SN - Senegal 118
BD - Bangladesh 114
GB - Regno Unito 108
NG - Nigeria 79
IN - India 73
ES - Italia 63
JP - Giappone 59
FI - Finlandia 48
HK - Hong Kong 46
NL - Olanda 45
MX - Messico 42
PL - Polonia 41
SE - Svezia 41
ID - Indonesia 37
ZA - Sudafrica 33
AR - Argentina 30
IQ - Iraq 26
TR - Turchia 26
BE - Belgio 20
UZ - Uzbekistan 19
EC - Ecuador 18
VE - Venezuela 16
AT - Austria 15
CL - Cile 15
KE - Kenya 15
CH - Svizzera 14
BJ - Benin 13
CO - Colombia 13
AE - Emirati Arabi Uniti 12
AU - Australia 12
CR - Costa Rica 12
CZ - Repubblica Ceca 12
JM - Giamaica 12
LT - Lituania 12
PK - Pakistan 12
GR - Grecia 10
IR - Iran 10
MA - Marocco 10
LB - Libano 9
HU - Ungheria 8
PY - Paraguay 8
TN - Tunisia 8
DZ - Algeria 6
EG - Egitto 6
IL - Israele 6
SA - Arabia Saudita 6
PE - Perù 5
RS - Serbia 5
AZ - Azerbaigian 4
BG - Bulgaria 4
MY - Malesia 4
NP - Nepal 4
OM - Oman 4
UY - Uruguay 4
AL - Albania 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
JO - Giordania 3
KZ - Kazakistan 3
TH - Thailandia 3
BB - Barbados 2
DK - Danimarca 2
ET - Etiopia 2
GE - Georgia 2
HR - Croazia 2
LV - Lettonia 2
PA - Panama 2
PH - Filippine 2
PS - Palestinian Territory 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
EE - Estonia 1
EU - Europa 1
GT - Guatemala 1
GY - Guiana 1
IM - Isola di Man 1
KG - Kirghizistan 1
LY - Libia 1
Totale 17.295
Salva come PNG Salva come JPEG
Città #
Dallas 1.822
Singapore 1.051
Santa Clara 802
Chandler 584
San Jose 565
Moscow 538
Houston 483
Ashburn 458
Dublin 410
Catania 379
Chicago 340
Abidjan 307
Jacksonville 284
Hefei 229
Boardman 187
Seoul 187
Beijing 167
Los Angeles 145
Lauterbourg 125
Dakar 118
Nanjing 115
Cambridge 109
Andover 108
Lawrence 108
Toronto 102
Civitanova Marche 98
Council Bluffs 92
New York 89
Ho Chi Minh City 81
Rome 78
Bremen 60
Buffalo 59
São Paulo 59
Wilmington 56
Hanoi 51
Des Moines 50
Tokyo 50
San Mateo 47
The Dalles 45
Hong Kong 42
Naples 40
Columbus 39
Lagos 39
Grafing 35
Munich 35
Shenyang 35
Nanchang 33
Atlanta 32
Saint Petersburg 32
Warsaw 32
Montreal 31
Abuja 29
Denver 28
London 27
Messina 27
Orem 27
Brooklyn 26
Changsha 26
Ottawa 26
Jiaxing 25
Milan 24
Johannesburg 22
Hebei 21
Poplar 21
Frankfurt am Main 20
Helsinki 20
Amsterdam 19
Brussels 19
Jakarta 19
Rio de Janeiro 18
Tianjin 18
Da Nang 17
Palermo 17
Phoenix 17
Pune 17
Chennai 16
Falls Church 15
Mexico City 15
San Francisco 15
Seattle 15
Haiphong 14
Lappeenranta 14
Madrid 14
Paris 14
San Giovanni la Punta 14
Tashkent 14
Turku 14
Belo Horizonte 13
Cotonou 13
Marseille 12
San Gregorio di Catania 12
Dong Ket 11
Port Harcourt 11
Stockholm 11
Augusta 10
Baghdad 10
Bologna 10
Ningbo 10
Norwalk 10
Pozzallo 10
Totale 11.910
Salva come PNG Salva come JPEG
Nome #
Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders 477
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 413
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 322
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 231
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 207
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 205
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 201
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 197
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 196
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 188
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 187
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands 180
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 180
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 171
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 165
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 164
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 161
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 161
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 160
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 158
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 154
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 154
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 153
Intercellular communication and ion channels in neuropathic pain chronicization 152
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 149
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 149
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 147
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 146
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 145
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 142
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 142
Design of Small Molecules for Oncological and Neurodegenerative Diseases 140
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 140
MOR/DOR targeting: an useful strategy in pain management 139
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 138
Dual-target ligands and pain: our experience 137
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 136
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 136
From plant to bench: natural products as source for analgesic drug development. 135
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 134
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 134
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 133
Analgesici oppioidi: nuove opportunità nella terapia del dolore 133
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 133
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 132
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 132
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 131
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 131
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 131
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 130
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 130
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 129
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 125
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 125
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 125
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 123
Analgesici oppioidi 122
Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies 119
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment 118
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 117
Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity 117
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 116
Synthesis of (+)-(1'R,2'S) and (1'S,2'R)-6,11 -dimethyl-1,2,3,4,5,6-hexahydro-3-[[2'-(alkoxycarbonyl)-2'- phenylcycloprophy]methyl]-2,6-methano-3-benzazocin-8-ol. Comparison of the affinities for sigma(1) and opioid receptors with in the diastereoisomeric MPCB and CCB 116
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 116
Design, synthesis and biological evaluation of MOR agonist/HDACi hybrid compounds: a new potential therapeutic strategy for persistent pain management 115
Multitarget opioid ligands in pain relief: New players in an old game 115
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 115
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 113
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 112
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 112
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 111
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 111
Progress in the development of more effective and safer analgesics for pain management 110
In-vitro evaluation of a new benzomorphan-based ligand 109
DESIGN, SYNTHESIS, MOLECULAR MODELING AND PHARMACOLOGICAL EVALUATION OF NOVEL DIAZABICYCLO[4.3.0]NONANE AND 2,7-DIAZASPIRO[3.5]NONANE AS SIGMA RECEPTORS LIGANDS 108
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 107
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 105
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 105
Evaluation of N-substitution in 6,7-benzomorphan compounds 104
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 104
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 103
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 103
Investigation of Tau-Dependent Epigenetic Reprogramming in Alzheimer’s Disease 102
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 101
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 101
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 100
New developments in opioid receptors ligands 99
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 99
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 99
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 98
Idebenone: Novel strategies to improve its systemic and local efficacy 98
Design, Synthesis, and Evaluation of Novel (−)‐cis‐N‐Normetazocine Derivatives: In Vitro and Molecular Modeling Insights 97
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics for Pain Treatment 96
NOVEL N-NORMETAZOCINE DERIVATIVES WITH SIGMA-1 RECEPTOR ANTAGONIST PROFILE AS POTENTIAL ANALGESICS FOR INFLAMMATORY PAIN MANAGEMENT 96
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 94
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 94
PET imaging of the opioid system using radioligands: Synthetic approaches and translational applications 93
Modulation of opioid receptor profile of LP1 analogues through the introduction of different N-substituents 93
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 93
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 93
Totale 13.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.953
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.953
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022927 99 104 9 24 134 11 119 33 84 26 36 248
2022/20231.755 139 95 29 238 131 263 6 341 359 34 80 40
2023/20241.080 55 136 51 40 56 258 67 108 8 30 185 86
2024/20253.374 83 516 150 226 662 424 229 134 218 260 224 248
2025/20268.285 470 387 2.036 506 1.059 1.411 788 199 418 448 298 265
2026/2027165 165 0 0 0 0 0 0 0 0 0 0 0
Totale 17.644